title: Therapeutic applications of the insulin-like growth factors.
abstract: The potential therapeutic applications of the insulin-like growth factors (IGFs) are broad. This review focuses on treatment of humans with recombinant human IGF-I (rhIGF-I), and with a rhIGF-I/IGF binding protein-3 (IGFBP-3) complex. Several groups of patients have been treated effectively, including individuals with growth hormone insensitivity syndrome (GHIS) secondary to GH receptor deficiency, to IGF-I gene deletion, or to defects in GH signal transduction pathways, patients with type 1 and type 2 diabetes mellitus, or individuals with severe insulin resistance syndromes. In each of these conditions rhIGF-I therapy has been demonstrated to be of clear clinical benefit. Other conditions, which may potential targets for therapy with rhIGF-I or rhIGF-I/IGFBP-3, include chronic inflammatory or nutritional disorders such as Crohn's disease, juvenile chronic arthritis, or cystic fibrosis. Therapy with IGFs has not been attempted in these disorders yet, in part because of lack of adequate supplies. Recently, the newly developed rhIGF-I/IGFBP-3 complex has been used in early clinical studies. Pharmacokinetic analyses in patients with diabetes mellitus and GHIS have suggested that a more physiological profile of serum IGF-I results. Improved glycaemic control has been reported in type 1 and type 2 diabetes in adults. A therapeutic trial in naïve children with GHIS is currently under way.
authors.affiliation: Research Centre in Clinical and Molecular Endocrinology, William Harvey Research Institute, Queen Mary's School of Medicine and Dentistry, Queen Mary's, University of London, London, UK. m.o.savage@qmul.ac.uk
authors.forename: Martin O
authors.initials: MO
authors.lastname: Savage
authors.forename: Cecilia
authors.initials: C
authors.lastname: Camacho-Hübner
authors.forename: David B
authors.initials: DB
authors.lastname: Dunger
mesh_terms: D000293:Adolescent; D000328:Adult; D003920:Diabetes Mellitus / Q000188:drug therapy*; D030342:Genetic Diseases, Inborn / Q000188:drug therapy; D006130:Growth Disorders / Q000188:drug therapy*; D006801:Humans; D007333:Insulin Resistance; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000627:therapeutic use; D046150:Laron Syndrome / Q000188:drug therapy*; D008297:Male; D011994:Recombinant Proteins; D013002:Somatomedins / Q000172:deficiency / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D018972:Insulin-Like Growth Factor Binding Protein 3; D011994:Recombinant Proteins; D013002:Somatomedins